Clinical Implications of MicroRNAs in Human Glioblastoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2013 Feb 14

PMID 23403472

Citations 32

Authors

Masahiro Mizoguchi

Yanlei Guan

Koji Yoshimoto

Nobuhiro Hata

Toshiyuki Amano

Akira Nakamizo

Tomio Sasaki

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is one of the most common and dismal brain tumors in adults. Further elucidation of the molecular pathogenesis of GBM is mandatory to improve the overall survival of patients. A novel small non-coding RNA molecule, microRNA (miRNA), appears to represent one of the most attractive target molecules contributing to the pathogenesis of various types of tumors. Recent global analyses have revealed that several miRNAs are clinically implicated in GBM, with some reports indicating the association of miRNA dysregulation with acquired temozolomide (TMZ) resistance. More recent studies have revealed that miRNAs could play a role in cancer stem cell (CSC) properties, contributing to treatment resistance. In addition, greater impact might be expected from miRNA-targeted therapies based on tumor-derived exosomes that contain numerous functional miRNAs, which could be transferred between tumor cells and surrounding structures. Tumor-derived miRNAs are now considered to be a novel molecular mechanism promoting the progression of GBM. Establishment of miRNA-targeted therapies based on miRNA dysregulation of CSCs could provide effective therapeutic strategies for TMZ-resistant GBM. Recent progress has revealed that miRNAs are not only putative biological markers for diagnosis, but also one of the most promising targets for GBM treatment. Here in, we summarize the translational aspects of miRNAs in the diagnosis and treatment of GBM.

Citing Articles

Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.

Squalli Houssaini A, Lamrabet S, Nshizirungu J, Senhaji N, Sekal M, Karkouri M Vaccines (Basel). 2024; 12(6).

PMID: 38932383 PMC: 11209492. DOI: 10.3390/vaccines12060655.

Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies.

Tluli O, Al-Maadhadi M, Al-Khulaifi A, Akomolafe A, Al-Kuwari S, Al-Khayarin R Cancers (Basel). 2023; 15(17).

PMID: 37686489 PMC: 10486509. DOI: 10.3390/cancers15174213.

Two Sides of The Same Coin: Normal and Tumoral Stem Cells, The Relevance of In Vitro Models and Therapeutic Approaches: The Experience with Zika Virus in Nervous System Development and Glioblastoma Treatment.

Tinnirello R, Chinnici C, Miceli V, Busa R, Bulati M, Gallo A Int J Mol Sci. 2023; 24(17).

PMID: 37686355 PMC: 10487988. DOI: 10.3390/ijms241713550.

Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.

Wang Y, Malik S, Suh H, Xiao Y, Deng Y, Fan R Sci Adv. 2023; 9(6):eabq7459.

PMID: 36753549 PMC: 9908025. DOI: 10.1126/sciadv.abq7459.

Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier.

Sharma R, Calderon C, Vivas-Mejia P Front Med Technol. 2022; 3:678593.

PMID: 35047931 PMC: 8757885. DOI: 10.3389/fmedt.2021.678593.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Weller M, Stupp R, Hegi M, Wick W . Individualized targeted therapy for glioblastoma: fact or fiction?. Cancer J. 2012; 18(1):40-4. DOI: 10.1097/PPO.0b013e318243f6c9. View

Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C . miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One. 2012; 7(3):e33844. PMC: 3313940. DOI: 10.1371/journal.pone.0033844. View

Li Y, Zhao S, Zhen Y, Li Q, Teng L, Asai A . A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells. Brain Tumor Pathol. 2011; 28(3):209-14. DOI: 10.1007/s10014-011-0037-1. View

Kim T, Huang W, Park R, Park P, Johnson M . A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res. 2011; 71(9):3387-99. PMC: 3085663. DOI: 10.1158/0008-5472.CAN-10-4117. View

Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer H . Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2009; 20(3):539-50. PMC: 8094849. DOI: 10.1111/j.1750-3639.2009.00328.x. View

Li Y, Guessous F, Zhang Y, diPierro C, Kefas B, Johnson E . MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009; 69(19):7569-76. PMC: 2756313. DOI: 10.1158/0008-5472.CAN-09-0529. View

Godlewski J, Nowicki M, Bronisz A, Williams S, Otsuki A, Nuovo G . Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008; 68(22):9125-30. DOI: 10.1158/0008-5472.CAN-08-2629. View

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F . A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64. PMC: 2718498. DOI: 10.1186/gb-2009-10-6-r64. View

10.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

11.

Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E . MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer. 2009; 125(6):1407-13. DOI: 10.1002/ijc.24522. View

12.

Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C, Sabatino G . Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4):1351-8. DOI: 10.1016/j.bbrc.2005.07.030. View

13.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

14.

Genovese G, Ergun A, Shukla S, Campos B, Hanna J, Ghosh P . microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov. 2012; 2(8):736-49. PMC: 3911772. DOI: 10.1158/2159-8290.CD-12-0111. View

15.

Srinivasan S, Patric I, Somasundaram K . A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011; 6(3):e17438. PMC: 3069027. DOI: 10.1371/journal.pone.0017438. View

16.

Rao S, Santosh V, Somasundaram K . Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol. 2010; 23(10):1404-17. DOI: 10.1038/modpathol.2010.135. View

17.

Chen Y, Gelfond J, McManus L, Shireman P . Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics. 2009; 10:407. PMC: 2753550. DOI: 10.1186/1471-2164-10-407. View

18.

Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G . MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012; 47(2):346-56. DOI: 10.1007/s12031-012-9759-8. View

19.

Ng W, Yan D, Zhang X, Mo Y, Wang Y . Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair (Amst). 2010; 9(11):1170-5. PMC: 2970684. DOI: 10.1016/j.dnarep.2010.08.007. View

20.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood M . Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4):341-5. DOI: 10.1038/nbt.1807. View